Two-stage designs optimal under the alternative hypothesis for phase II cancer clinical trials. (2010)

First Author: Mander AP
Attributed to:  Hub in Trials Methodology Research (MRC Biostatistics Unit, Cambridge) funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.cct.2010.07.008

PubMed Identifier: 20678585

Publication URI: http://europepmc.org/abstract/MED/20678585

Type: Journal Article/Review

Volume: 31

Parent Publication: Contemporary clinical trials

Issue: 6

ISSN: 1551-7144